Data gathered: September 7
Alternative Data for Eledon Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,299 | Sign up | Sign up | Sign up |
| Twitter Followers | 190 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 26 | Sign up | Sign up | Sign up |
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
| Price | $2.54 |
| Target Price | Sign up |
| Volume | 35,910 |
| Market Cap | $102M |
| Year Range | $1.54 - $3.19 |
| Dividend Yield | 0% |
| PE Ratio | 5.71 |
| Industry | Biotechnology |
In the news
Eledon Pharmaceuticals completes enrollment for Phase 2 BESTOW trialSeptember 3 - Thefly.com |
|
 |
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Decreases By 6.8%September 2 - ETF Daily News |
|
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per ShareAugust 23 - ETF Daily News |
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024August 18 - InvestorPlace |
|
|
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 16.1% in JulyAugust 16 - ETF Daily News |
Eledon Pharmaceuticals: A Strong Buy on Clinical Progress and Strategic PositioningAugust 15 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 4.4M | -4.4M | -45M | 0 | 0.000 |
| Q1 '24 | 0 | 3.5M | -3.5M | -24M | -11M | -0.340 |
| Q4 '23 | 0 | 3.3M | -3.3M | -9.6M | -10M | -0.290 |
| Q3 '23 | 0 | 3.3M | -3.3M | -9.9M | -11M | -0.350 |
| Q2 '23 | 0 | 3.2M | -3.2M | -66M | -10M | -0.400 |
Insider Transactions View All
| BIOTECHNOLOGY VALUE FUND L P filed to buy 220,460 shares at $0. May 13 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 232,068 shares at $0. May 13 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 2,633,679 shares at $0. May 13 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 3,361,803 shares at $0. May 13 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 2,526,238 shares at $0. May 13 '24 |
Similar companies
Read more about Eledon Pharmaceuticals (ELDN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Eledon Pharmaceuticals?
The Market Cap of Eledon Pharmaceuticals is $102M.
What is Eledon Pharmaceuticals' PE Ratio?
As of today, Eledon Pharmaceuticals' PE (Price to Earnings) ratio is 5.71.
What is the current stock price of Eledon Pharmaceuticals?
Currently, the price of one share of Eledon Pharmaceuticals stock is $2.54.
How can I analyze the ELDN stock price chart for investment decisions?
The ELDN stock price chart above provides a comprehensive visual representation of Eledon Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eledon Pharmaceuticals shares. Our platform offers an up-to-date ELDN stock price chart, along with technical data analysis and alternative data insights.
Does ELDN offer dividends to its shareholders?
As of our latest update, Eledon Pharmaceuticals (ELDN) does not offer dividends to its shareholders. Investors interested in Eledon Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Eledon Pharmaceuticals?
Some of the similar stocks of Eledon Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.